Educational content on VJNeurology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESOC 2021 | The promise of neuroprotective agents in the reperfusion era

Despite a plethora of preclinical evaluations of putative neuroprotective agents, the translation from bench to beside has failed to produce successful treatment strategies. However, acute stroke therapy has now entered the era of highly effective reperfusion, with mechanical thrombectomy and intravenous thrombolysis representing the new standard of care. Ángel Chamorro, MD, PhD, Hospital Clinic of Barcelona & University of Barcelona, Barcelona, Spain, talks on how this advancement will aid the development of neuroprotective agents. Successful reperfusion may allow drugs to reach the brain when they could not before. Prof. Chamorro believes that there is a great future for neuroprotection, and both novel drugs and previously investigated drugs should be studied in this new reperfusion era. This interview took place at the European Stroke Organisation Conference (ESOC), 2021.

Choose your cookie settings

VJNeurology uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.